Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Pfizer Inc. BOSULIF® (bosutinib) prescribing information. New York, NY; 2017.
2. Pfizer Japan Inc. BOSULIF® (bosutinib) prescribing information. Japan; 2020.
3. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231–7.
4. Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, et al. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021;114:65–78.
5. Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, et al. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. Int J Hematol. 2020;112:24–32.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献